Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Saved in:
| Title: | Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. |
|---|---|
| Authors: | Martin RC 2nd; Division of Surgical Oncology, University of Louisville School of Medicine, Louisville, Kentucky.; James Graham Brown Cancer Center, Louisville, Kentucky., Scoggins CR; Division of Surgical Oncology, University of Louisville School of Medicine, Louisville, Kentucky.; James Graham Brown Cancer Center, Louisville, Kentucky., Schreeder M; Clearview Cancer Institute, Huntsville, Alabama., Rilling WS; Froedtert Medical College, Milwaukee, Wisconsin., Laing CJ; Interventional Radiology, Sutter Health, Sacramento, California., Tatum CM; Norton Radiology Associates, Louisville, Kentucky., Kelly LR; Norton Radiology Associates, Louisville, Kentucky., Garcia-Monaco RD; Hospital Italiano, Buenos Aires, Argentina., Sharma VR; James Graham Brown Cancer Center, Louisville, Kentucky.; Division of Medical Oncology, University of Louisville School of Medicine, Louisville, Kentucky., Crocenzi TS; Providence Medical Center, Portland, Oregon., Strasberg SM; Siteman Cancer Center, Washington University in Saint Louis/Barnes-Jewish Hospital, Saint Louis, Missouri. |
| Source: | Cancer [Cancer] 2015 Oct 15; Vol. 121 (20), pp. 3649-58. Date of Electronic Publication: 2015 Jul 06. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
